tbuckley/cabot-search huggingface dataset:
Inhalable metal–organic framework-mediated cuproptosis combined with PD-L1 checkpoint blockade for lung metastasis synergistic immunotherapy
Authors: Chongzheng Yan, Ying Liu, Guozhi Zhao, Huatian Yang, Huaiyou Lv, Genju Li, Yuhan Li, Yaqing Fu, Fengqin Sun, Yafei Feng, Yizhe Li, Zhongxi Zhao
Journal: Acta Pharmaceutica Sinica B (2024)

Cuproptosis shows enormous application prospects in lung metastasis treatment. However, the glycolysis, Cu+ efflux mechanisms, and insufficient lung drug accumulation severely restrict cuproptosis efficacy. Herein, an inhalable poly(2-(N-oxide-N,N-diethylamino)ethyl methacrylate) (OPDEA)-coated copper-based metal–organic framework encapsulating pyruvate dehydrogenase kinase 1 siRNA (siPDK) is constructed for mediating cuproptosis and subsequently promoting lung metastasis immunotherapy, namely OMP. After inhalation, OMP shows highly efficient lung accumulation and long-term retention, ascribing to the OPDEA-mediated pulmonary mucosa penetration. Within tumor cells, OMP is degraded to release Cu2+ under acidic condition, which will be reduced to toxic Cu+ to induce cuproptosis under glutathione (GSH) regulation. Meanwhile, siPDK released from OMP inhibits intracellular glycolysis and adenosine-5ʹ-triphosphate (ATP) production, then blocking the Cu+ efflux protein ATP7B, thereby rendering tumor cells more sensitive to OMP-mediated cuproptosis. Moreover, OMP-mediated cuproptosis triggers immunogenic cell death (ICD) to promote dendritic cells (DCs) maturation and CD8+ T cells infiltration. Notably, OMP-induced cuproptosis up-regulates membrane-associated programmed cell death-ligand 1 (PD-L1) expression and induces soluble PD-L1 secretion, and thus synergizes with anti-PD-L1 antibodies (aPD-L1) to reprogram immunosuppressive tumor microenvironment, finally yielding improved immunotherapy efficacy. Overall, OMP may serve as an efficient inhalable nanoplatform and afford preferable efficacy against lung metastasis through inducing cuproptosis and combining with aPD-L1.
DDAH1 promotes neurogenesis and neural repair in cerebral ischemia
Authors: Qiming Gao, Pinfei Ni, Yilin Wang, Peiyun Huo, Xiaojie Zhang, Sihan Wang, Fuyao Xiao, Yixuan Li, Wei Feng, Juntao Yuan, Teng Zhang, Qiang Li, Boyu Fan, Yuhao Kan, Zhirui Li, Yimiao Qi, Junfei Xing, Zhenghong Yang, Haixiao Cheng, Xinran Gao, Xiaoyan Feng, Ming Xue, Yang Liu, Yumin Luo, Zhongbing Lu, Yuming Zhao
Journal: Acta Pharmaceutica Sinica B (2024)

Choline acetyltransferase (ChAT)-positive neurons in neural stem cell (NSC) niches can evoke adult neurogenesis (AN) and restore impaired brain function after injury, such as acute ischemic stroke (AIS). However, the relevant mechanism by which ChAT
Expanded Systematic Evidence Map for Hundreds of Per- and Polyfluoroalkyl Substances (PFAS) and Comprehensive PFAS Human Health Dashboard
Authors: Avanti V. Shirke, Elizabeth G. Radke, Cynthia Lin, Robyn Blain, Nicole Vetter, Courtney Lemeris, Pamela Hartman, Heidi Hubbard, Michelle Angrish, Xabier Arzuaga, Johanna Congleton, Allen Davis, Laura V. Dishaw, Ryan Jones, Richard Judson, J. Phillip Kaiser, Andrew Kraft, Lucina Lizarraga, Pamela D. Noyes, Grace Patlewicz, Michele Taylor, Antony J. Williams, Kristina A. Thayer, Laura M. Carlson
Journal: Environmental Health Perspectives (2024)

Per- and polyfluoroalkyl substances (PFAS) encompass a class of chemically and structurally diverse compounds that are extensively used in industry and detected in the environment. The US Environmental Protection Agency (US EPA) 2021 PFAS Strategic Roadmap describes national research plans to address the challenge of PFAS.
Hospital Fugue
Authors: Heather Claire Treseler
Journal: JAMA (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Neonatal Outcomes After COVID-19 Vaccination in Pregnancy
Authors: Mikael Norman, Maria C. Magnus, Jonas Söderling, Petur B. Juliusson, Lars Navér, Anne K. Örtqvist, Siri Håberg, Olof Stephansson
Journal: JAMA (2024)

Importance Better knowledge about neonatal adverse events after COVID-19 vaccination during pregnancy could help address concerns about vaccine safety. Objective To evaluate the risks of neonatal adverse events after exposure to COVID-19 vaccination during pregnancy. Design, Setting, and Participants Population-based cohort study including all infants in Sweden and Norway born from June 2021 to January 2023. Unique personal identity numbers were used to link individual information from different national registers. Exposure Administration of any mRNA vaccine against COVID-19 during pregnancy, irrespective of previous vaccination, number of doses during pregnancy, or vaccine manufacturer. Main Outcomes and Measures Outcomes were neonatal conditions with bleeding/thrombosis or inflammation/infection; disorders of the central nervous system; circulatory, respiratory, or gastrointestinal problems; and neonatal mortality. Statistical methods included logistic regression adjusted for characteristics of the pregnant individuals, with additional restricted and stratified analyses. Results Of 196 470 newborn infants included (51.3% male, 93.8% born at term, 62.5% born in Sweden), 94 303 (48.0%) were exposed to COVID-19 vaccination during pregnancy. Exposed infants exhibited no increased odds of adverse neonatal outcomes, and they exhibited lower odds for neonatal nontraumatic intracranial hemorrhage (event rate, 1.7 vs 3.2/1000; adjusted odds ratio [aOR], 0.78 [95% CI, 0.61-0.99]), hypoxic-ischemic encephalopathy (1.8 vs 2.7/1000; aOR, 0.73 [95% CI, 0.55-0.96]), and neonatal mortality (0.9 vs 1.8/1000; aOR, 0.68 [95% CI, 0.50-0.91]). Subgroup analyses found a similar association between vaccination during pregnancy and lower neonatal mortality; subgroups were restricted to infants delivered by individuals unvaccinated before pregnancy, individuals vaccinated before pregnancy, individuals vaccinated after a general recommendation of vaccination during pregnancy was issued, and individuals without COVID-19 infection during pregnancy. Analyses restricted to term infants, singleton births, or infants without birth defects yielded similar results. Stratifying the analysis by vaccine manufacturer did not attenuate the association between vaccination and low neonatal mortality. Conclusions and Relevance In this large population-based study, vaccination of pregnant individuals with mRNA COVID-19 vaccines was not associated with increased risks of neonatal adverse events in their infants.
Rh Sensitization and Induced Abortion
Authors: Robert S. Galen, Harvey W. Kaufman, Mark I. Evans
Journal: JAMA (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cefiderocol either in monotherapy or combination versus best available therapy in the treatment of carbapenem-resistant Acinetobacter baumannii infections: A systematic review and meta-analysis
Authors: Lorenzo Onorato, Ilaria de Luca, Caterina Monari, Nicola Coppola
Journal: Journal of Infection (2024)

BackgroundThe best treatment for carbapenem-resistant Acinetobacter baumannii (CRAB) infections is still a matter of debate.ObjectivesTo describe the outcomes of patients treated with cefiderocol for CRAB infections, and to compare the efficacy of cefiderocol versus best available therapy (BAT).Data sourcesWe searched MEDLINE, the Cochrane Library and EMBASE to screen original reports published up to September 2023Study eligibility criteriaRCTs and observational studies investigating 30-day mortality, clinical failure, microbiological failure or rate of ADRs of patients treated with cefiderocol or BATParticipantsPatients with infections due to CRABInterventionsCefiderocol in monotherapy or in combination with other potentially active agents or BATAssessment of risk of biasWe used the Cochrane Risk of Bias Tool for RCTs, and the Newcastle Ottawa scale for observational studies.Methods of data synthesisWe conducted a meta-analysis pooling Risk ratios (RRs) through random effect models.ResultsWe screened 801 original reports, and 18 studies (2 RCTs, 13 cohort studies and 3 case-series) were included in the analysis, for a total 733 patients treated with cefiderocol, and 473 receiving the BAT. Among patients receiving cefiderocol, the 30-day mortality rate was 42% (95% CI 38-47%), the rate of microbiological failure 48% (95% CI 31-65%), the clinical failure rate 43% (95% CI 32-55%), and the rate of ADRs was 3% (95% CI 1-6%). A lower mortality rate was observed among patients receiving cefiderocol monotherapy as compared to those treated with combination regimens (RR: 0.64; 95% CI: 0.43-0.94, p=0.024). We found a significantly lower mortality rate (RR: 0.74; 95% CI: 0.57-0.95, p=0.02) and a lower rate of ADRs (RR: 0.28; 95% CI: 0.09-0.91, p=0.03) in the group treated with cefiderocol as compared to BAT. No difference was observed in microbiological and clinical failure rate.ConclusionsOur data strengthen the efficacy and safety profile of cefiderocol in CRAB infections.
Serum Urate and Recurrent Gout
Authors: Natalie McCormick, Chio Yokose, Gregory J. Challener, Amit D. Joshi, Sruthi Tanikella, Hyon K. Choi
Journal: JAMA (2024)

Approximately 12 million adults in the US have a history of gout, but whether serum urate levels can help predict recurrence is unclear.
Sedentary Behavior and Dementia
Authors: Frederick M. Hecht
Journal: JAMA (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Rh Sensitization and Induced Abortion
Authors: Kenneth J. Moise, Elizabeth A. Abels
Journal: JAMA (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Bespoke Gene Therapy Consortium: facilitating development of AAV gene therapies for rare diseases
Authors: P. J. Brooks, Timothy M. Miller, Frédéric Revah, Junghae Suh, Bradley R. Garrison, Lawrence C. Starke, Timothy K. MacLachlan, Edward G. Neilan, Gopa Raychaudhuri, Sadik H. Kassim, Jean Dehdashti, Joni L. Rutter
Journal: Nature Reviews Drug Discovery (2024)
Rh Sensitization and Induced Abortion—Reply
Authors: Sarah Horvath, Courtney A. Schreiber, Eline T. Luning Prak
Journal: JAMA (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Thyroid Cancer
Authors: Laura Boucai, Mark Zafereo, Maria E. Cabanillas
Journal: JAMA (2024)

Importance Approximately 43 720 new cases of thyroid carcinoma are expected to be diagnosed in 2023 in the US. Five-year relative survival is approximately 98.5%. This review summarizes current evidence regarding pathophysiology, diagnosis, and management of early-stage and advanced thyroid cancer. Observations Papillary thyroid cancer accounts for approximately 84% of all thyroid cancers. Papillary, follicular (≈4%), and oncocytic (≈2%) forms arise from thyroid follicular cells and are termed well-differentiated thyroid cancer. Aggressive forms of follicular cell-derived thyroid cancer are poorly differentiated thyroid cancer (≈5%) and anaplastic thyroid cancer (≈1%). Medullary thyroid cancer (≈4%) arises from parafollicular C cells. Most cases of well-differentiated thyroid cancer are asymptomatic and detected during physical examination or incidentally found on diagnostic imaging studies. For microcarcinomas (≤1 cm), observation without surgical resection can be considered. For tumors larger than 1 cm with or without lymph node metastases, surgery with or without radioactive iodine is curative in most cases. Surgical resection is the preferred approach for patients with recurrent locoregional disease. For metastatic disease, surgical resection or stereotactic body irradiation is favored over systemic therapy (eg, lenvatinib, dabrafenib). Antiangiogenic multikinase inhibitors (eg, sorafenib, lenvatinib, cabozantinib) are approved for thyroid cancer that does not respond to radioactive iodine, with response rates 12% to 65%. Targeted therapies such as dabrafenib and selpercatinib are directed to genetic mutations ( BRAF , RET , NTRK , MEK ) that give rise to thyroid cancer and are used in patients with advanced thyroid carcinoma. Conclusions Approximately 44 000 new cases of thyroid cancer are diagnosed each year in the US, with a 5-year relative survival of 98.5%. Surgery is curative in most cases of well-differentiated thyroid cancer. Radioactive iodine treatment after surgery improves overall survival in patients at high risk of recurrence. Antiangiogenic multikinase inhibitors and targeted therapies to genetic mutations that give rise to thyroid cancer are increasingly used in the treatment of metastatic disease.
Early Sepsis-Associated Acute Kidney Injury and Obesity
Authors: Yoon Hae Ahn, Si Mong Yoon, Jinwoo Lee, Sang-Min Lee, Dong Kyu Oh, Su Yeon Lee, Mi Hyeon Park, Chae-Man Lim, Hong Yeul Lee, Jeongwon Heo, Jae-myeong Lee, Kyung Chan Kim, Yeon Joo Lee, Young-Jae Cho, Sung Yoon Lim, Youjin Chang, Kyeongman Jeon, Ryoung-Eun Ko, Gee Young Suh, Suk-Kyung Hong, Sang-Bum Hong, Woo Hyun Cho, Sang Hyun Kwak, Heung Bum Lee, Jong-Joon Ahn, Gil Myeong Seong, Song-I Lee, Sunghoon Park, Tai Sun Park, Su Hwan Lee, Eun Young Choi, Jae Young Moon, Hyung Koo Kang
Journal: JAMA Network Open (2024)

The prevalence of obesity is increasing in the intensive care unit (ICU). Although obesity is a known risk factor for chronic kidney disease, its association with early sepsis-associated acute kidney injury (SA-AKI) and their combined association with patient outcomes warrant further investigation.
Sedentary Behavior and Dementia—Reply
Authors: David A. Raichlen, Yann C. Klimentidis, Gene E. Alexander
Journal: JAMA (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Errors in Percentage Calculations
Journal: JAMA (2024)

Matthieu Schmidt, MD; David Hajage, MD; Guillaume Lebreton, MD; Martin Dres, MD; Christophe Guervilly, MD; Jean Christophe Richard, MD; Romain Sonneville, MD; Hadrien Winiszewski, MD; Gregoire Muller, MD; Gaëtan Beduneau, MD; Emmanuelle Mercier, MD; Hadrien Roze, MD; Mathieu Lesouhaitier, MD; Nicolas Terzi, MD; Arnaud W. Thille, MD; Isaura Laurent, MD; Antoine Kimmoun, MD; Alain Combes, MD; PRONECMO Investigators, the REVA Network, and the International ECMO Network (ECMONet); Charles Edouard Luyt; Guillaume Hekimian ; Nicolas Brechot ; Juliette Chommeloux; Marc Pineton de Chambrun ; Ouriel Saura; David Levy ; Lucie Lefevre; Benjamin Assouline; Petra Bahroum; Melchior Gautier; Pascal Leprince; Charles Juvin; Pierre Demondion ; Elodie Bergue; Pichoy Danial; Hamed Al-kabani; Karl Bounader; Thibaut Schoell; Cosimo D'Allesandro; Côme Bureau; Julien Le Marec; Julien Mayaux; Maxens Decavèle; Alexandre Demoule ; Robin Deleris ; Safaa Nemlaghi; Marie Lecronier; Gilles Capellier; Gael Piton; Francois Belon; Thibault Vieille; Valentin Lafay; Camille Manfait; Romain Tapponnier; Nicolas Belin ; Arnaud Gacouin ; Jean-Marc Tadié; Laurent Papazian; Sami Hraiech; Jean-Marie Forel; Antoine Roch; Mélanie Adda; Florence Daviet; Ines Gragueb-Chatti; Laura Textoris; Jean-François Timsit ; Lila Bouadma; Etienne de Montmollin; Fariza Lamara; Véronique Deiler; Marylou Para; Patrick Nataf; Sylia Zmihi; Paul Henri Wicky; Juliette Patrier; Pierre Jaquet; Bruno Levy ; Pierre Perez; Carine Thivilier; Mathieu Mattei; Clément Haddadi; Matthieu Kozutski; Pablo Maureira; Hodane Yonis; Medhi Mezidi; Louis Chauvelot; William Danjou; Francois Dhelft; Laurent Bitker; Clotilde Bettinger; Pauline Bernon ; Grégoire Jolly; Dorothée Carpentier; Mai-Anh Nay; Thierry Boulain ; Toukif Kamel; Francois Barbier; Anne Bretagnol; Armelle Mathonnet; Maxime Desgrouas; Marie Skarzynski; Benjamin Repusseau; Florian Sigaud; Guillaume Rigault; Louis-Marie Galerneau ; Carole Schwebel ; Clara Candille ; Anaïs Dartevel; Joanna Bougnaud; Emanuele Turbil; Stephan Ehrmann; Denis Garot; Charlotte Salmon; Sylvain Le Pape; Francois Arrivé